Company intelligence / Profile preview
MedTrace Pharma
Copenhagen, Denmarkmedtracepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead program (^15O-water PET) has dosed over 2000 patients across Denmark, Sweden, and the US under research or exemption protocols. The pivotal RAPID-WATER-FLOW Phase 3 trial aims to demonstrate diagnostic accuracy/safety of ^15O-water PET for coronary artery disease. Early results have enabled first-in-US patient dosing using their automated system. aQuant software automates quantitative image analysis but remains pre-market approval.
- Therapeutic areas
- OncologyEndocrinologyCardiovascular
- Modalities
- RadiopharmaceuticalDeviceSoftware
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Brigham and Women’s Hospital / Harvard Medical School (RAPID-WATER-FLOW trial)Aarhus University Hospital DenmarkaQuant team/software founders (merged in 2018)
Beyond the preview
Go deeper on MedTrace Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedTrace Pharma.